How much profit has Starpharma Holdings made this year?
Starpharma Holdings has made -8.17 M AUD this year.
Starpharma Holdings Net Income 2024
Starpharma Holdings Net Income
-8.17 M AUD
Ticker
SPL.AX
ISIN
AU000000SPL0
WKN
796461
In 2024, Starpharma Holdings's profit amounted to -8.17 M AUD, a -47.79% increase from the -15.64 M AUD profit recorded in the previous year.
The Starpharma Holdings Net Income history
| YEAR | NET INCOME (undefined AUD) |
|---|---|
| 2025e | -17.74 |
| 2024 | -8.17 |
| 2023 | -15.64 |
| 2022 | -16.15 |
| 2021 | -19.73 |
| 2020 | -14.68 |
| 2019 | -14.25 |
| 2018 | -10.29 |
| 2017 | 8.2 |
| 2016 | -22.68 |
| 2015 | -18.95 |
| 2014 | -14.64 |
| 2013 | -5.23 |
| 2012 | -13.66 |
| 2011 | -8.93 |
| 2010 | -6.38 |
| 2009 | -4.13 |
| 2008 | -7.49 |
| 2007 | -7.25 |
| 2006 | -7.52 |
| 2005 | -7.59 |
Starpharma Holdings Revenue, EBIT, Net Income AU000000SPL0 · 796461
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Starpharma Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Starpharma Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Starpharma Holdings’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Starpharma Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Starpharma Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Starpharma Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Starpharma Holdings’s growth potential.
Starpharma Holdings Revenue, EBIT and net profit per share
| Date | Starpharma Holdings Revenue | Starpharma Holdings EBIT | Starpharma Holdings Net Income |
|---|---|---|---|
| 2025e | 4.75 M undefined | -15.45 M undefined | -17.74 M undefined |
| 2024 | 9.76 M undefined | -8.17 M undefined | -8.17 M undefined |
| 2023 | 4.21 M undefined | -15.77 M undefined | -15.64 M undefined |
| 2022 | 4.9 M undefined | -16.42 M undefined | -16.15 M undefined |
| 2021 | 2.15 M undefined | -21.07 M undefined | -19.73 M undefined |
| 2020 | 7.12 M undefined | -14.68 M undefined | -14.68 M undefined |
| 2019 | 2.72 M undefined | -14.25 M undefined | -14.25 M undefined |
| 2018 | 4.96 M undefined | -10.29 M undefined | -10.29 M undefined |
| 2017 | 3.65 M undefined | -15.22 M undefined | 8.2 M undefined |
| 2016 | 4.57 M undefined | -21.29 M undefined | -22.68 M undefined |
| 2015 | 1.7 M undefined | -18.95 M undefined | -18.95 M undefined |
| 2014 | 1.25 M undefined | -14.63 M undefined | -14.64 M undefined |
| 2013 | 2.43 M undefined | -5.22 M undefined | -5.23 M undefined |
| 2012 | 2.9 M undefined | -13.65 M undefined | -13.66 M undefined |
| 2011 | 3.3 M undefined | -8.91 M undefined | -8.93 M undefined |
| 2010 | 5.91 M undefined | -6.36 M undefined | -6.38 M undefined |
| 2009 | 9.82 M undefined | -4.3 M undefined | -4.13 M undefined |
| 2008 | 9.92 M undefined | -8.12 M undefined | -7.49 M undefined |
| 2007 | 9.55 M undefined | -7.75 M undefined | -7.25 M undefined |
| 2006 | 6.99 M undefined | -6.86 M undefined | -7.52 M undefined |
| 2005 | 2.05 M undefined | -8.34 M undefined | -7.59 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2005 | 2.05 M AUD | -8.34 M AUD | -7.59 M AUD |
| 2006 | 6.99 M AUD | -6.86 M AUD | -7.52 M AUD |
| 2007 | 9.55 M AUD | -7.75 M AUD | -7.25 M AUD |
| 2008 | 9.92 M AUD | -8.12 M AUD | -7.49 M AUD |
| 2009 | 9.82 M AUD | -4.3 M AUD | -4.13 M AUD |
| 2010 | 5.91 M AUD | -6.36 M AUD | -6.38 M AUD |
| 2011 | 3.3 M AUD | -8.91 M AUD | -8.93 M AUD |
| 2012 | 2.9 M AUD | -13.65 M AUD | -13.66 M AUD |
| 2013 | 2.43 M AUD | -5.22 M AUD | -5.23 M AUD |
| 2014 | 1.25 M AUD | -14.63 M AUD | -14.64 M AUD |
| 2015 | 1.7 M AUD | -18.95 M AUD | -18.95 M AUD |
| 2016 | 4.57 M AUD | -21.29 M AUD | -22.68 M AUD |
| 2017 | 3.65 M AUD | -15.22 M AUD | 8.2 M AUD |
| 2018 | 4.96 M AUD | -10.29 M AUD | -10.29 M AUD |
| 2019 | 2.72 M AUD | -14.25 M AUD | -14.25 M AUD |
| 2020 | 7.12 M AUD | -14.68 M AUD | -14.68 M AUD |
| 2021 | 2.15 M AUD | -21.07 M AUD | -19.73 M AUD |
| 2022 | 4.9 M AUD | -16.42 M AUD | -16.15 M AUD |
| 2023 | 4.21 M AUD | -15.77 M AUD | -15.64 M AUD |
| 2024 | 9.76 M AUD | -8.17 M AUD | -8.17 M AUD |
| 2025e | 4.75 M AUD | -15.45 M AUD | -17.74 M AUD |
Starpharma Holdings stock margins AU000000SPL0 · 796461
The Starpharma Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Starpharma Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Starpharma Holdings.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Starpharma Holdings's sales revenue. A higher gross margin percentage indicates that the Starpharma Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Starpharma Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Starpharma Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Starpharma Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Starpharma Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Starpharma Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Starpharma Holdings Margin History
| Starpharma Holdings Gross margin | Starpharma Holdings Profit margin | Starpharma Holdings EBIT margin | Starpharma Holdings Profit margin |
|---|---|---|---|
| 2025e | 93.52 % | -325.53 % | -373.63 % |
| 2024 | 93.52 % | -83.69 % | -83.69 % |
| 2023 | 73.38 % | -374.83 % | -371.63 % |
| 2022 | 43.34 % | -335.11 % | -329.74 % |
| 2021 | 63.23 % | -979.45 % | -917.34 % |
| 2020 | 87.49 % | -206.3 % | -206.3 % |
| 2019 | 90.77 % | -524.04 % | -524.04 % |
| 2018 | 93.52 % | -207.48 % | -207.48 % |
| 2017 | 93.52 % | -417.22 % | 224.84 % |
| 2016 | 93.52 % | -465.46 % | -495.74 % |
| 2015 | 93.52 % | -1,116.38 % | -1,116.68 % |
| 2014 | 93.52 % | -1,170.4 % | -1,171.2 % |
| 2013 | 93.52 % | -214.81 % | -215.23 % |
| 2012 | 93.52 % | -470.69 % | -471.03 % |
| 2011 | 93.52 % | -270 % | -270.61 % |
| 2010 | 93.52 % | -107.61 % | -107.95 % |
| 2009 | 93.52 % | -43.79 % | -42.06 % |
| 2008 | 93.52 % | -81.85 % | -75.5 % |
| 2007 | 93.52 % | -81.15 % | -75.92 % |
| 2006 | 93.52 % | -98.14 % | -107.58 % |
| 2005 | 93.52 % | -406.83 % | -370.24 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2005 | 93.52 % | -406.83 % | -370.24 % |
| 2006 | 93.52 % | -98.14 % | -107.58 % |
| 2007 | 93.52 % | -81.15 % | -75.92 % |
| 2008 | 93.52 % | -81.85 % | -75.5 % |
| 2009 | 93.52 % | -43.79 % | -42.06 % |
| 2010 | 93.52 % | -107.61 % | -107.95 % |
| 2011 | 93.52 % | -270 % | -270.61 % |
| 2012 | 93.52 % | -470.69 % | -471.03 % |
| 2013 | 93.52 % | -214.81 % | -215.23 % |
| 2014 | 93.52 % | -1,170.4 % | -1,171.2 % |
| 2015 | 93.52 % | -1,116.38 % | -1,116.68 % |
| 2016 | 93.52 % | -465.46 % | -495.74 % |
| 2017 | 93.52 % | -417.22 % | 224.84 % |
| 2018 | 93.52 % | -207.48 % | -207.48 % |
| 2019 | 90.77 % | -524.04 % | -524.04 % |
| 2020 | 87.49 % | -206.3 % | -206.3 % |
| 2021 | 63.23 % | -979.45 % | -917.34 % |
| 2022 | 43.34 % | -335.11 % | -329.74 % |
| 2023 | 73.38 % | -374.83 % | -371.63 % |
| 2024 | 93.52 % | -83.69 % | -83.69 % |
| 2025e | 93.52 % | -325.53 % | -373.63 % |
Starpharma Holdings Aktienanalyse
What does Starpharma Holdings do?
Starpharma Holdings Ltd is an Australian company specializing in the development of innovative solutions in the fields of pharmacy and biotechnology. The company was founded in 1996 and has since written an impressive history full of successful developments and numerous partnerships. The main business of Starpharma focuses on the development and commercialization of drugs and other health products based on dendrimer technology. One of the most advanced applications of dendrimer technology is VivaGel, a topical gel for the prevention of sexually transmitted diseases, particularly HPV (Human Papillomavirus). VivaGel is based on a dendrimer that acts both as an antiviral agent and an antibiotic, capable of preventing infection by different types of HPV. The product has already undergone Phase III clinical trials and is currently being marketed worldwide. In addition to VivaGel, Starpharma also offers dendrimer-based technologies and services in the field of drug development. The company has formed numerous partnerships with major pharmaceutical companies such as AstraZeneca, GSK, and Merck, and is involved in the development of drugs for cancer, autoimmune diseases, and infectious diseases. Furthermore, Starpharma has expanded its dendrimer technology to other industries, such as agriculture, where dendrimers can contribute to improving soil quality and reducing pesticide use. In this sector, Starpharma has also formed partnerships with agricultural companies such as Adama and Nufarm. Overall, Starpharma is a company that has experienced significant growth in recent years and continues to focus on the development of new and innovative products and solutions. Its core competence in dendrimer technology has allowed it to establish itself as a key player in various industries and build numerous partnerships with global companies. With its diverse range of products and services and a strong focus on research and development, Starpharma can be considered an important player in the field of biotechnology and healthcare innovations. Indicate the sector in starpharma specialize in. Starpharma Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Starpharma Holdings's Profit Margins
The profit margins of Starpharma Holdings represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Starpharma Holdings's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Starpharma Holdings's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Starpharma Holdings's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Starpharma Holdings’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Starpharma Holdings stock
How has the profit developed compared to last year?
The profit has increased by -47.79% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Starpharma Holdings publish its earnings?
Starpharma Holdings publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Starpharma Holdings?
The profits of Starpharma Holdings are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Starpharma Holdings?
You can learn more about the earnings of Starpharma Holdings by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Starpharma Holdings pay?
Over the past 12 months, Starpharma Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Starpharma Holdings is expected to pay a dividend of 0 AUD.
What is the dividend yield of Starpharma Holdings?
The current dividend yield of Starpharma Holdings is .
When does Starpharma Holdings pay dividends?
Starpharma Holdings pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Starpharma Holdings?
Starpharma Holdings paid dividends every year for the past 0 years.
What is the dividend of Starpharma Holdings?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Starpharma Holdings located?
Starpharma Holdings is assigned to the 'Health' sector.
Wann musste ich die Aktien von Starpharma Holdings kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Starpharma Holdings from 12/1/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 12/1/2024.
When did Starpharma Holdings pay the last dividend?
The last dividend was paid out on 12/1/2024.
What was the dividend of Starpharma Holdings in the year 2023?
In the year 2023, Starpharma Holdings distributed 0 AUD as dividends.
In which currency does Starpharma Holdings pay out the dividend?
The dividends of Starpharma Holdings are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Starpharma Holdings
Our stock analysis for Starpharma Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Starpharma Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Starpharma Holdings Revenue
- Starpharma Holdings Net Income
- Starpharma Holdings P/E
- Starpharma Holdings P/S
- Starpharma Holdings EBIT
- Starpharma Holdings Dividend
- Starpharma Holdings Stocks
- Starpharma Holdings Market capitalization
- Starpharma Holdings Debt
- Starpharma Holdings Liabilities
- Starpharma Holdings Equity
- Starpharma Holdings AAQS
- Starpharma Holdings Employees
- Starpharma Holdings ROE
- Starpharma Holdings ROA
- Starpharma Holdings ROCE
